Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597923360> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2597923360 abstract "e14566 Background: JX-594 is a targeted oncolytic vaccinia virus designed to selectively replicate in and destroy cancer cells with epidermal growth factor receptor (EGFR)/ ras pathway activation. Direct oncolysis plus GM-CSF expression is accompanied by tumor vascular disruption and anti-tumoral immunity (Reviewed in Nat Rev Cancer 2009). JX-594 was well-tolerated intravenously (IV) (Nature 2011) and intratumorally (IT) (Lancet Oncol 2008). Complementary anti-tumor effects are predicted with JX-594 followed by sorafenib due to acute vascular disruption effects with JX-594 and anti-angiogenic effects with sorafenib. Methods: Treatment-refractory HCC patients received JX-594 for three weeks (Day 1 IV, Day 8 IT and Day 22 IT) followed by sorafenib. An IT boost dose of JX-594 at Week 12 was optional. The primary objective of the study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. Secondary objectives include disease control rate (DCR) based on mRECIST and/or Choi response criteria at Day 6 (optional), Day 25 (after JX-594 only), 6 and 12 weeks. Results: Twenty (20) patients were treated in this study; fifteen (15) were refractory to sorafenib. The sequential treatment regimen was well-tolerated. Transient flu-like symptoms (Grade 1-2) and transient leukopenia (lymphopenia, neutropenia) were the most common adverse events following JX-594 therapy. Sorafenib toxicities were consistent with the expected toxicity profile. At the time of this interim analysis, thirteen patients were evaluable for radiographic response by Choi criteria (mRECIST pending). After JX-594 alone at Day 25, 10 of 13 evaluable patients (77%) had Choi tumor responses (range 19-48% reduced enhancement). Following subsequent sorafenib therapy, 11 of 13 patients (85%) had Choi responses at Week 6-12, including 9 of 10 (90%) sorafenib-failure patients. Conclusions: JX-594 was well-tolerated and associated with Choi tumor responses following IV and IT injections in patients with advanced HCC. Subsequent sorafenib was associated with the expected toxicity profile. Further trials of JX-594 in HCC patients are warranted." @default.
- W2597923360 created "2017-04-07" @default.
- W2597923360 creator A5007343447 @default.
- W2597923360 creator A5008020207 @default.
- W2597923360 creator A5010240694 @default.
- W2597923360 creator A5016539137 @default.
- W2597923360 creator A5031127358 @default.
- W2597923360 creator A5033267651 @default.
- W2597923360 creator A5040676175 @default.
- W2597923360 creator A5044195657 @default.
- W2597923360 creator A5044968259 @default.
- W2597923360 creator A5047075962 @default.
- W2597923360 creator A5047433754 @default.
- W2597923360 creator A5054250864 @default.
- W2597923360 creator A5056969382 @default.
- W2597923360 creator A5066566375 @default.
- W2597923360 creator A5087683860 @default.
- W2597923360 date "2012-05-20" @default.
- W2597923360 modified "2023-09-26" @default.
- W2597923360 title "A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)." @default.
- W2597923360 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e14566" @default.
- W2597923360 hasPublicationYear "2012" @default.
- W2597923360 type Work @default.
- W2597923360 sameAs 2597923360 @default.
- W2597923360 citedByCount "2" @default.
- W2597923360 countsByYear W25979233602017 @default.
- W2597923360 countsByYear W25979233602022 @default.
- W2597923360 crossrefType "journal-article" @default.
- W2597923360 hasAuthorship W2597923360A5007343447 @default.
- W2597923360 hasAuthorship W2597923360A5008020207 @default.
- W2597923360 hasAuthorship W2597923360A5010240694 @default.
- W2597923360 hasAuthorship W2597923360A5016539137 @default.
- W2597923360 hasAuthorship W2597923360A5031127358 @default.
- W2597923360 hasAuthorship W2597923360A5033267651 @default.
- W2597923360 hasAuthorship W2597923360A5040676175 @default.
- W2597923360 hasAuthorship W2597923360A5044195657 @default.
- W2597923360 hasAuthorship W2597923360A5044968259 @default.
- W2597923360 hasAuthorship W2597923360A5047075962 @default.
- W2597923360 hasAuthorship W2597923360A5047433754 @default.
- W2597923360 hasAuthorship W2597923360A5054250864 @default.
- W2597923360 hasAuthorship W2597923360A5056969382 @default.
- W2597923360 hasAuthorship W2597923360A5066566375 @default.
- W2597923360 hasAuthorship W2597923360A5087683860 @default.
- W2597923360 hasConcept C104317684 @default.
- W2597923360 hasConcept C126322002 @default.
- W2597923360 hasConcept C143998085 @default.
- W2597923360 hasConcept C159047783 @default.
- W2597923360 hasConcept C185592680 @default.
- W2597923360 hasConcept C2522874641 @default.
- W2597923360 hasConcept C2778019345 @default.
- W2597923360 hasConcept C2778695046 @default.
- W2597923360 hasConcept C2781356689 @default.
- W2597923360 hasConcept C40767141 @default.
- W2597923360 hasConcept C502942594 @default.
- W2597923360 hasConcept C55493867 @default.
- W2597923360 hasConcept C71924100 @default.
- W2597923360 hasConcept C82210918 @default.
- W2597923360 hasConceptScore W2597923360C104317684 @default.
- W2597923360 hasConceptScore W2597923360C126322002 @default.
- W2597923360 hasConceptScore W2597923360C143998085 @default.
- W2597923360 hasConceptScore W2597923360C159047783 @default.
- W2597923360 hasConceptScore W2597923360C185592680 @default.
- W2597923360 hasConceptScore W2597923360C2522874641 @default.
- W2597923360 hasConceptScore W2597923360C2778019345 @default.
- W2597923360 hasConceptScore W2597923360C2778695046 @default.
- W2597923360 hasConceptScore W2597923360C2781356689 @default.
- W2597923360 hasConceptScore W2597923360C40767141 @default.
- W2597923360 hasConceptScore W2597923360C502942594 @default.
- W2597923360 hasConceptScore W2597923360C55493867 @default.
- W2597923360 hasConceptScore W2597923360C71924100 @default.
- W2597923360 hasConceptScore W2597923360C82210918 @default.
- W2597923360 hasLocation W25979233601 @default.
- W2597923360 hasOpenAccess W2597923360 @default.
- W2597923360 hasPrimaryLocation W25979233601 @default.
- W2597923360 hasRelatedWork W1827137208 @default.
- W2597923360 hasRelatedWork W2003884720 @default.
- W2597923360 hasRelatedWork W2015786402 @default.
- W2597923360 hasRelatedWork W2020849247 @default.
- W2597923360 hasRelatedWork W2043089638 @default.
- W2597923360 hasRelatedWork W2060006845 @default.
- W2597923360 hasRelatedWork W2084510043 @default.
- W2597923360 hasRelatedWork W2244305851 @default.
- W2597923360 hasRelatedWork W2267264910 @default.
- W2597923360 hasRelatedWork W2323566532 @default.
- W2597923360 hasRelatedWork W2606654289 @default.
- W2597923360 hasRelatedWork W2761424420 @default.
- W2597923360 hasRelatedWork W2776551433 @default.
- W2597923360 hasRelatedWork W2896240692 @default.
- W2597923360 hasRelatedWork W2978579182 @default.
- W2597923360 hasRelatedWork W3013377956 @default.
- W2597923360 hasRelatedWork W3020400386 @default.
- W2597923360 hasRelatedWork W3199073182 @default.
- W2597923360 hasRelatedWork W337617016 @default.
- W2597923360 hasRelatedWork W785204982 @default.
- W2597923360 isParatext "false" @default.
- W2597923360 isRetracted "false" @default.
- W2597923360 magId "2597923360" @default.
- W2597923360 workType "article" @default.